Dave Simpson, Iksuda
A Celltrion-backed biotech is developing 'tunable' conjugates to crack solid tumors — and it has eyes on the clinic
The next generation of antibody-drug conjugates has become a big area of focus in oncology venture capital, with a slate of biotechs arguing they have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
